Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford, UK.
Endocrinol Diabetes Metab. 2024 Jan;7(1):e467. doi: 10.1002/edm2.467.
This study evaluates the predictive value of copeptin for syndrome of inappropriate antidiuresis (SIAD) postpituitary transsphenoidal surgery (TSS).
Data from 133 consecutive patients undergoing TSS (November 2017-October 2022) at Oxford University Hospitals NHS trust are presented in this retrospective study.
Logistic regression (LR) and receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic utility of copeptin. The Mann-Whitney U test was used to compare copeptin levels between the SIAD and no SIAD groups.
Fourteen patients (10.8%) developed SIAD. Copeptin was available in 121, 53 and 87 patients for Days 1, 241 and 8 post-TSS, respectively. LR for Day 1 copeptin to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 42 0.84-1.20, p = .99), area under-ROC curve (AUC) was 0.49; Day 2 copeptin OR was 0.65 (95%CI 0.39-1.19, 43 p = .77), AUC was 0.57 LR for Day 1 sodium to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 0.85-1.21, p = .99), AUC was 0.50.
In conclusion, our data provide no evidence for copeptin as a predictive marker for post-TSS SIAD.
本研究评估加压素原(copeptin)对垂体经蝶窦手术后(TSS)抗利尿激素分泌不当综合征(SIAD)的预测价值。
本回顾性研究纳入了牛津大学医院 NHS 信托基金 2017 年 11 月至 2022 年 10 月期间连续接受 TSS 的 133 例患者的数据。
采用逻辑回归(LR)和受试者工作特征(ROC)曲线评估 copeptin 的诊断效用。Mann-Whitney U 检验用于比较 SIAD 和非 SIAD 两组之间的 copeptin 水平。
14 例患者(10.8%)发生 SIAD。在 TSS 后第 1、24 和 8 天,分别有 121、53 和 87 例患者可获得 copeptin。第 1 天 copeptin 预测 SIAD 的 LR 比值比(OR)为 1.0(95%CI 42 0.84-1.20,p=0.99),ROC 曲线下面积(AUC)为 0.49;第 2 天 copeptin 的 OR 为 0.65(95%CI 0.39-1.19,p=0.77),AUC 为 0.57。第 1 天钠预测 SIAD 的 LR 比值比(OR)为 1.0(95%CI 0.85-1.21,p=0.99),AUC 为 0.50。
综上所述,本研究数据并未提供 copeptin 作为 TSS 后 SIAD 预测标志物的证据。